Endoscopic submucosal dissection (ESD) has been successfully performed in thrombocytopenic conditions such as in patients with liver cirrhosis but successful ESD for early gastric cancer (EGC) in hematologic diseases has rarely been reported. A 52-year-old male patient, who had previously been diagnosed with myelodysplastic syndrome 2 years ago, was admitted to our hospital for ESD of EGC. ESD was performed successfully in this patient after platelet concentrates transfusion on the day of ESD. ESD might be an option for the treatment of EGC in thrombocytopenia due to hematologic diseases when optimal supportive managements are applied. (Korean J Gastroenterol 2015;65:173-176) 
INTRODUCTION

Endoscopic submucosal dissection (ESD) is now accepted
as an alternative to surgery for the treatment of early gastric cancer (EGC). Because the incidence of complications, such as bleeding or perforation, are high, the utility of this treatment modality can be limited in patients with a high probability of bleeding. Although ESD has been successfully performed in thrombocytopenic conditions such as in patients with liver cirrhosis 1 successful ESD for EGC in hematologic diseases has rarely been reported. In this case, we report a patient who, after being diagnosed with myelodysplastic syndrome (MDS) and accompanying EGC, was successfully treated with ESD.
CASE REPORT
A 52-year-old male patient, who had previously been diagnosed with MDS 2 years ago, was admitted to our hospital for ESD of EGC. As for MDS, he was in the low risk group according to the International Prognostic Scoring System 2 and was under conservative management with regular follow up. On initial gastroscopy, an EGC lesion was noted at the posterior wall of the gastric antrum (Fig. 1A) . A well-differentiated ad- A follow-up gastroscopy, which was performed eight weeks after ESD, showed complete healing of the lesion (Fig. 3 ). 
DISCUSSION
Bleeding and perforation are common complications of ESD: bleeding is observed in 15.6% of patients, and perforation is observed in 1.2%. 3 Despite the high rate of bleeding, this procedure has been performed successfully in patients with bleeding diatheses, such as liver cirrhosis or chronic renal failure. 4, 5 However, there have been no reports on successful ESD for EGC in patients with thrombocytopenia due to hematologic diseases.
MDS comprise a group of biologically and clinically heterogeneous clonal hematopoietic neoplasms characterized by aberrant myeloid differentiation, dysplastic changes, ineffective hematopoiesis and increasing genomic instability that manifest clinically into peripheral blood cytopenias and variably increased rates of leukemic progression. In the low risk groups, life expectancy is considerable and malignancies of other organs should be treated properly. 6 In patients with hematologic diseases, severe thrombocytopenia frequently develops as a consequence of the disease or its treatment. In most cases, platelet concentrates are administered as prophylaxis, to increase low platelet counts and reduce the risk of bleeding. However, the degree to which prophylactic platelet transfusions benefit patients with severe thrombocytopenia has been unclear. A recent trial suggested that a policy of giving platelet concentrates only as treatment for bleeding might become a new standard of care in selected patients, although the primary end point was a reduction in the number of platelet transfusions, not clinical outcome such as bleeding. 7 In general platelet counts of 50,000/mm 3 are considered sufficient for surgery in most cases. 8 However, guidelines of optimal platelet counts for endoscopic resection have not been suggested. One systematic review on ESD of gastric neoplasms in liver cirrhosis patients reported that complication rates were not different when platelet counts were over 50,000/mm 3 . 9 Considering these reports, we think that platelet counts of 50,000/mm 3 might be considered sufficient for endoscopic resection for gastric neoplasms.
To prevent ESD-related bleeding, pharmacological treatment with proton pump inhibitors (PPIs) as well as endoscopic hemostasis should be considered. Re-bleeding up to 72 hours after endoscopic treatment is often caused by the dissolution of formed fibrin clots by gastric acid. Because platelet aggregation, coagulation, and fibrinolysis on gastric hemorrhagic ulcers strongly depend on intragastric pH levels, ways to neutralize pH levels should be considered.
Studies concerning post-ESD ulcer healing and post-operation hemorrhage have reported that PPI therapy gives good healing rates for post-ESD ulcers, and it is also effective for the prevention of post-operative hemorrhage. 10, 11 In this case, the patient was diagnosed with MDS, and the patient's platelet count was 21,000/mm 3 on the day of the ESD, but the transfusion of platelet concentrates enabled us to perform the procedure without bleeding. PPI administration also might have contributed to the prevention of post-ESD bleeding.
In conclusion, ESD can be performed successfully in patients with thromobcytopenias due to hematologic diseases such as MDS, when platelet concentrates and PPIs are administered properly.
